Search results for "peripheral"

showing 10 items of 1028 documents

Tachykinin-, calcitonin gene-related peptide-, and protein gene product 9.5-immunoreactive nerve fibers in alveolar walls of mammals.

1991

The presence and distribution of the presumed pan-neural marker protein gene product 9.5 (PGP)- and peptide-immunoreactive (ir) nerve fibers in alveolar walls of various species was investigated by light microscopic single and double staining immunohistochemistry. PGP-, tachykinin (TK)-, and calcitonin gene-related peptide (CRGP)-ir fibers were sparsely distributed in a similar pattern in alveolar walls of all species investigated. No vasoactive intestinal peptide-, peptide histidine isoleucine-, galanin-, and opioid-ir nerve fibers could be detected. PGP-ir fibers outnumbered those staining for TKs and CGRP. There was partial coexistence of PGP and TK as well as of TK and CRGP. PGP-, TK-, …

medicine.medical_specialtyAlveolar EpitheliumCalcitonin Gene-Related PeptideVasoactive intestinal peptideGuinea PigsCalcitonin gene-related peptideBiologyAlveolar cellsDogsNerve FibersSpecies SpecificityInternal medicineCricetinaeTachykininsmedicineAnimalsGalaninMammalsintegumentary systemMesocricetusGeneral NeuroscienceNeuropeptidesrespiratory systemMolecular biologyRatsPulmonary Alveolimedicine.anatomical_structureEndocrinologyCalcitoninPeripheral nervous systemCatsPulmonary alveolusUbiquitin ThiolesteraseBiomarkersNeuroscience letters
researchProduct

13 LASER-EVOKED POTENTIALS IN PERIPHERAL NEUROPATHY

2007

medicine.medical_specialtyAnesthesiology and Pain MedicinePeripheral neuropathyLaser-Evoked Potentialsbusiness.industryOphthalmologyMedicinebusinessmedicine.diseaseEuropean Journal of Pain
researchProduct

Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.

2017

Myelodysplastic Syndromes are oligo-clonal stem cell disorders that are associated with cytopenias in the peripheral blood. Major causes for morbidity and mortality in myelodysplastic syndromes (MDS) patients are infections mostly due to bacteria or fungi. Beside leucopenia per se in affected patients, function of white blood cells particularly that of neutrophils seems to be impaired. Here we summarize the available data on infections in MDS patients in general and particularly those treated with 5-azacitidine.

medicine.medical_specialtyAntimetabolites AntineoplasticNeutropeniaAzacitidineInfections03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansIn patientMortalityInfection Controlbusiness.industryMyelodysplastic syndromesHematologyGeneral MedicineAntibiotic Prophylaxismedicine.diseasePeripheral blood030220 oncology & carcinogenesisMyelodysplastic SyndromesAzacitidineStem cellMorbiditybusiness030215 immunologymedicine.drugEuropean journal of haematology
researchProduct

Cilostazol and atherogenic dyslipidemia: a clinically relevant effect

2011

Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia.The effects of cilostazol on plasma lipids, lipoproteins, apolipoproteins and postprandial lipemia are reviewed. A literature search (using Medline and Scopus) was performed up to 24 October 2010. The authors also manually reviewed the references of selected articles for any pertinent material.Cilostazol is able to significantly lower plasma triglyceride levels, with a concomitant increase in high-density lipoprot…

medicine.medical_specialtyApolipoprotein BTetrazolescilostazol atherogenic dyslipidemiaPhosphodiesterase 3 InhibitorsPeripheral Arterial Diseasechemistry.chemical_compoundDiabetes mellitusInternal medicineHumansMedicinePharmacology (medical)DyslipidemiasPharmacologymedicine.diagnostic_testbiologybusiness.industryCholesterolGeneral MedicineAtherosclerosismedicine.diseaseLipidsCyclic Nucleotide Phosphodiesterases Type 3Intermittent claudicationCilostazolCilostazolPostprandialEndocrinologyDiabetes Mellitus Type 2chemistrybiology.proteinlipids (amino acids peptides and proteins)medicine.symptombusinessLipid profileLipoproteinmedicine.drug
researchProduct

Metabolic syndrome and peripheral arterial disease.

2014

medicine.medical_specialtyArterial diseasebusiness.industryInternal medicinemedicineCardiologyGeneral MedicineMetabolic syndromebusinessmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareMetabolic syndrome peripheral arterial diseasePeripheralRevista clinica espanola
researchProduct

Diabetes Mellitus and Its Impact on Patient-Profile and In-Hospital Outcomes in Peripheral Artery Disease

2021

Background: In patients with peripheral artery disease (PAD), the impact of diabetes mellitus (DM) on patient-profile and adverse in-hospital events is not well investigated. Methods: The German nationwide inpatient sample 2005–2019 was used for this analysis. Hospitalized PAD patients were stratified for DM and the influence of DM on patient-profile and adverse in-hospital events was investigated. Results: Our study comprised 2,654,871 hospitalizations (54.3% aged ≥70 years, 36.7% females) of patients with PAD in Germany 2005–2019. Among these, 864,691 (32.6%) patients had DM and 76,716 (2.9%) died during hospitalization. Diabetic PAD patients revealed an aggravated cardiovascular profile …

medicine.medical_specialtyArterial diseasebusiness.industrymedicine.medical_treatmentRGeneral MedicineDiseasemedicine.diseaseperipheral artery diseaseArticlemyocardial infarctionHospital outcomesAmputationInternal medicineDiabetes mellitusamputationdiabetes mellitusmedicinePatient profileMedicineMyocardial infarctionAdverse effectbusinessJournal of Clinical Medicine
researchProduct

Position Paper on Young Vascular Surgeons Training of the Mediterranean Federation for the Advancing of Vascular Surgery (MeFAVS): State of the Art a…

2021

ABSTRACT The Mediterranean Federation for the Advancing of Vascular Surgery (MeFAVS) was founded in 2018, with the aim to promote cooperation among vascular professionals within Mediterranean countries. Due to its prominent social and economic impact on national health systems, diabetic peripheral artery was selected as the very first topic to be investigated by the federation. In this second paper, different experiences from delegates of participating countries were shared to define common strategies to harmonize, standardize, and optimize education and training in the Vascular Surgery specialty.

medicine.medical_specialtyArterial diseasemedia_common.quotation_subjectVascular SurgerySettore MED/22 - Chirurgia VascolareTraining (civil)Peripheral Arterial DiseaseState (polity)medicineMediterranean SeaHumansTrainingEconomic impact analysisVascular surgery specialtymedia_commonNational healthSurgeonsbusiness.industryMediterranean RegionInternship and ResidencyGeneral MedicineVascular surgeryendovascular surgery; Mediterranean sea; training; vascular surgeryEducation Medical GraduateFamily medicineEndovascular SurgeryPosition paperSurgeryClinical CompetenceCurriculumCardiology and Cardiovascular MedicinebusinessVascular Surgical ProceduresDiabetic AngiopathiesLearning CurveProgram EvaluationSpecialization
researchProduct

Single staged hybrid approach for multilevel aortic-iliac-femoral-popliteal disease

2020

Highlights • Multilevel peripheral arterial disease in diabetic patients is cause of amputation. • Herein we report a case of critic limb ischemia addressed by hybrid procedure. • Hybrid procedure outcomes seem to be as good as with open revascularization. • Hybrid procedure show less morbidity and shorter intensive care and hospital stay.

medicine.medical_specialtyArterial diseasemedicine.medical_treatmentDiseaseRevascularizationRenal artery stenosisSettore MED/22 - Chirurgia Vascolare03 medical and health sciences0302 clinical medicineIntensive caremedicine.arteryCase reportPeripheral arterial diseasemedicineRenal arteryEndovascularRevascularization.business.industryRevascularizationBlood flowHybrid approachmedicine.diseaseSurgeryHybrid procedure030220 oncology & carcinogenesis030211 gastroenterology & hepatologySurgerybusinessInternational Journal of Surgery Case Reports
researchProduct

Gait Impairment in a Rat Model of Focal Cerebral Ischemia

2012

The availability of proper tests for gait evaluation following cerebral ischemia in rats has been limited. The automated, quantitative CatWalk system, which was initially designed to measure gait in models of spinal cord injury, neuropathic pain, and peripheral nerve injury, is said to be a useful tool for the study of motor impairment in stroke animals. Here we report our experiences of using CatWalk XT with rats subjected to transient middle cerebral artery occlusion (MCAO), during their six-week followup. Large corticostriatal infarct was confirmed by MRI in all MCAO rats, which was associated with severe sensorimotor impairment. In contrast, the gait impairment was at most mild, which i…

medicine.medical_specialtyArticle Subjectbusiness.industryIschemiata3141medicine.diseaseta3112SurgeryPreferred walking speedGait (human)Gait impairmentPhysical medicine and rehabilitationPeripheral nerve injuryNeuropathic painmedicineNeurology. Diseases of the nervous systemcardiovascular diseasesNeurology (clinical)RC346-429businessSpinal cord injuryStrokeResearch ArticleStroke Research and Treatment
researchProduct

Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growth

2007

This study examined the dose-dependent efficacy of erythropoietin (EPO) for preventing and/or treating cisplatin (CDDP) induced peripheral neurotoxicity (CINP), and its influence on tumour treatment and growth. Rats received eight intraperitoneal (ip) injections of 2 mg/kg CDDP twice weekly. EPO co-administered (50 or 10 microg/kg ip, three times/week) had a dose-dependent effect, partially preventing CINP, but 0.5 microg/kg ip was not effective. The neuroprotective effect lasted at least 5 weeks after the last dose of EPO and CDDP. In addition, EPO (50 microg/kg ip three times/week) after the last injection of CDDP still induced a significant recovery of CINP. In a separate experiment in r…

medicine.medical_specialtyCancer ResearchPeripheral neuropathyNeural ConductionNeurophysiologyAntineoplastic AgentsHindlimbHematocritNeuroprotectionAntineoplastic AgentInternal medicinemedicinePathologyAnimalsRats WistarErythropoietinCisplatincisplatin; Erythropoietin; peripheral neuropathy; tumor growthmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryAnimalNeurotoxicityPeripheral Nervous System DiseasesMammary Neoplasms ExperimentalTumour growthHematologymedicine.diseaseRatsHindlimbDose–response relationshipPeripheral neuropathyEndocrinologyOncologyHematocritErythropoietinRatFemalePeripheral Nervous System DiseaseCisplatinbusinessCell Divisionmedicine.drug
researchProduct